Play Earnings CallPlay Earnings Call
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call March 2, 2026 8:30 AM EST
Company Participants
Allison Wey – Senior Vice President of Investor Relations & Corporate Communications
John Shannon – CEO & Director
Steven Pieper – Chief Financial Officer
Conference Call Participants
David Amsellem – Piper Sandler & Co., Research Division
Brandon Folkes – H.C. Wainwright & Co, LLC, Research Division
Chase Knickerbocker – Craig-Hallum Capital Group LLC, Research Division
Yuchen Ding – Jefferies LLC, Research Division
Byunghyun Ahn – Leerink Partners LLC, Research Division
Jason Dorr – Oppenheimer & Co. Inc., Research Division
Jenna Davidner – Barclays Bank PLC, Research Division
Presentation
Operator
Hello, everyone. Thank you for joining us, and welcome to the Xeris Biopharma Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions]
I will now hand the call over to Allison Wey, Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Allison Wey
Senior Vice President of Investor Relations & Corporate Communications
Thank you, Warren. Good morning, and welcome to the Xeris Biopharma 2025 Full Year Financial Results Conference Call. Earlier this morning, we issued a press release detailing our 2025 financial and operating results and financial guidance for 2026. This press release is available on our website. Joining me on the call today is John Shannon, our CEO; and Steve Pieper, our CFO.
Following our prepared remarks, we will open the call for questions. Before we begin, I’d like to remind you that today’s discussion will include forward-looking statements regarding Xeris’ future expectations, plans, strategies, objectives and financial performance. These forward-looking statements are based on management’s current assumptions and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied. For a discussion of these risks and uncertainties, please refer to the risk factors described in our filings with the SEC. Any forward-looking statements made
